Acute resveratrol supplementation in coronary artery disease: towards patient stratificationVisa övriga samt affilieringar
2020 (Engelska)Ingår i: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, nr 1, s. 14-19Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
OBJECTIVE: Resveratrol (RV) is a polyphenol with antioxidant, anti-inflammatory and cardio-protective properties. Our objective was to investigate whether acute supplementation with high doses of RV would improve flow-mediated dilation (FMD) and oxygen consumption (VO2) kinetics in older coronary artery disease (CAD) patients.
DESIGN: We employed a placebo-controlled, single-blind, crossover design in which ten participants (aged 66.6 ± 7.8 years) received either RV or placebo (330 mg, 3x day-1) during three consecutive days plus additional 330 mg in the morning of the fourth day with a seven-day wash-out period in-between. On the fourth day, FMD of the brachial artery and VO2 on-kinetics were determined. Results; RV improved FMD in patients who had undergone coronary artery bypass grafting (CABG; -1.4 vs. 5.0%; p = 0.004), but not in those who had undergone percutaneous coronary intervention (PCI; 4.2 vs. -0.2%; NS).
CONCLUSION: Acute high dose supplementation with RV improved FMD in patients after CABG surgery but impaired FMD in patients who underwent PCI. The revascularization method-related differential effects of RV may be due to its direct effects on endothelial-dependent dilator responses. Our findings have important implications for personalized treatment and stratification of older CAD patients.
Ort, förlag, år, upplaga, sidor
Taylor & Francis, 2020. nr 1, s. 14-19
Nyckelord [en]
Aging, Antioxidant, Endothelial Dysfunction, Oxygen Uptake
Nationell ämneskategori
Kardiologi
Identifikatorer
URN: urn:nbn:se:rkh:diva-3018DOI: 10.1080/14017431.2019.1657584PubMedID: 31429599OAI: oai:DiVA.org:rkh-3018DiVA, id: diva2:1345302
2019-08-232019-08-232020-12-22Bibliografiskt granskad